Direct Healthcare Professional Communication (DHPC) on caspofungin: Avoid use of polyacrylonitrile membranes during continuous renal replacement therapy.
2025.10.09
Active substance: caspofungin
The marketing authorisation holders of caspofungin containing medicines would like to inform that during treatment with caspofungin the use of polyacrylonitrile membranes during continuous renal replacement therapy should be avoided, as cases have been reported in which caspofungin was ineffective in these patients.
Download DHPC/Information letter , Download_VeroeffentlichtAm_EN